Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Who is this study for? Patients with Hairy Cell Leukemia
What treatments are being studied? Cladribine s.c. Injection, HCL treatment
Status: Recruiting
Location: See all (76) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• Patients with histologically verified hairy cell leukemia
• Presence of hairy cells in the bone marrow and peripheral blood detected by positive TRAP staining and / or co expression if cell surface antigens cluster of differentiation (CD) 19/CD25 or CD19/CD103 (b-ly7)
• No previous cytostatic treatment (splenectomy or interferon treatment are allowed)
• Need for treatment
• Age at least 18 years old
• General state of health according to WHO 0-2
• Current histology, not older than 6 months
• Written consent by patient
Locations
Other Locations
Germany
Community based hemato-oncology medical office
RECRUITING
Ansbach
Community based hemato-oncology medical office
RECRUITING
Aschaffenburg
Rhön-Saale-Klinik gGmbH
RECRUITING
Bad Neustadt An Der Saale
Charité - Universitätsmedizin Berlin
RECRUITING
Berlin
Community based hemato-oncology medical office
RECRUITING
Berlin
Community based hemato-oncology medical office
RECRUITING
Bremen
Community based hemato-oncology medical office
RECRUITING
Celle
Community based hemato-oncology medical office
RECRUITING
Cottbus
Community based hemato-oncology medical office
RECRUITING
Darmstadt
Community based hemato-oncology medical office
RECRUITING
Dresden
Community based hemato-oncology medical office
RECRUITING
Duisburg
Klinik Duisburg-West
RECRUITING
Duisburg
Universitätsklinik Düsseldorf
RECRUITING
Düsseldorf
Community based hemato-oncology medical office
RECRUITING
Ehingen
Community based hemato-oncology medical office
RECRUITING
Erlangen
Community based hemato-oncology medical office
RECRUITING
Frankfurt
Krankenhaus Nordwest
RECRUITING
Frankfurt
Community based hemato-oncology medical office
RECRUITING
Freiburg Im Breisgau
Community based hemato-oncology medical office
RECRUITING
Friedrichshafen
Community based hemato-oncology medical office
RECRUITING
Fürth
Community based hemato-oncology medical office
RECRUITING
Germering
Community based hemato-oncology medical office
RECRUITING
Giessen
University Clinic | Medicinal Clinic IV
RECRUITING
Giessen
St.-Marien-Hospital
RECRUITING
Hagen
Community based hemato-oncology medical office
RECRUITING
Halle
Evangelisches Krankenhaus
RECRUITING
Hamm
Community based hemato-oncology medical office
RECRUITING
Hanau
Community based hemato-oncology medical office
RECRUITING
Heidelberg
Community based hemato-oncology medical office
RECRUITING
Herne
Marienkrankenhaus
RECRUITING
Herne
Community based hemato-oncology medical office
RECRUITING
Homberg (ohm)
Community based hemato-oncology medical office
RECRUITING
Kaiserslautern
Städtisches Klinikum
RECRUITING
Karlsruhe
Community based hemato-oncology medical office
RECRUITING
Kassel
Klinikum Kempten-Oberallgäu
RECRUITING
Kempten
Community based hemato-oncology medical office
NOT_YET_RECRUITING
Koblenz
Community based hemato-oncology medical office
RECRUITING
Krefeld
Community based hemato-oncology medical office
RECRUITING
Kronach
Community based hemato-oncology medical office
RECRUITING
Landau
Community based hemato-oncology medical office
RECRUITING
Landshut
Community based hemato-oncology medical office
RECRUITING
Landshut
Klinikum Leverkusen GmbH
RECRUITING
Leverkusen
Community based hemato-oncology medical office
RECRUITING
Lüdenscheid
St. Marienkrankenhaus
RECRUITING
Ludwigshafen
Universitätsklinik Mainz
RECRUITING
Mainz
Community based hemato-oncology medical office
RECRUITING
Marburg
Community based hemato-oncology medical office
RECRUITING
Mönchengladbach
Community based hemato-oncology medical office
RECRUITING
München
University Clinic Großhadern
RECRUITING
München
Community based hemato-oncology medical office
RECRUITING
Neumarkt
Community based hemato-oncology medical office
RECRUITING
Nuremberg
Community based hemato-oncology medical office
RECRUITING
Nuremberg
St. Clemens Hospital
RECRUITING
Oberhausen
St. Martinus-Hospital
RECRUITING
Olpe
Community based hemato-oncology medical office
RECRUITING
Osnabrück
St. Josefs-Krankenhaus
RECRUITING
Potsdam
Community based hemato-oncology medical office
RECRUITING
Rehling
Community based hemato-oncology medical office
RECRUITING
Rüsselsheim Am Main
Caritas Klinik St. Theresia
RECRUITING
Saarbrücken
Community based hemato-oncology medical office
RECRUITING
Schkeuditz
Kreiskrankenhaus Schotten
RECRUITING
Schotten
Community based hemato-oncology medical office
RECRUITING
Schweinfurt
Community based hemato-oncology medical office
RECRUITING
Siegen
St.-Marien-Krankenhaus
RECRUITING
Siegen
Diakonie - Klinikum Stuttgart
RECRUITING
Stuttgart
Community based hemato-oncology medical office
RECRUITING
Trier
Community based hemato-oncology medical office
RECRUITING
Tübingen
University Clinic Ulm
RECRUITING
Ulm
Städtisches Krankenhaus Villingen
RECRUITING
Villingen-schwenningen
Community based hemato-oncology medical office
RECRUITING
Weilheim
Sophien- und Hufeland Klinikum
RECRUITING
Weimar
Asklepios Nordseeklinik
RECRUITING
Westerland
Community based hemato-oncology medical office
RECRUITING
Wiesbaden
Dr. Horst-Schmidt-Kliniken
RECRUITING
Wiesbaden
Community based hemato-oncology medical office
RECRUITING
Wilhelmshaven
Community based hemato-oncology medical office
RECRUITING
Wolfsburg
Contact Information
Primary
Mathias J Rummel, Prof PhD
mathias.rummel@innere.med.uni-giessen.de
+4964198542
Backup
Juergen Barth
juergen.barth@innere.med.uni-giessen.de
+4964198542
Time Frame
Start Date: 2004-05
Estimated Completion Date: 2027-12
Participants
Target number of participants: 210
Treatments
Other: Cladribine s.c. injection, HCL treatment
Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
Related Therapeutic Areas
Sponsors
Leads: University of Giessen